CD80 and acute lymphoblastic leukemia: Among the 21 samples of B-ALL cells, CD80 and CD86 expression increased 100 % in 10 of 21 samples following treatment with Ara-C (Table 1, patient no. 1, 4, 5, 6, 9, 13, 15, 16, 20, 21).